马西替坦减轻TGF-β1诱导的肺纤维化及肺动脉高压进展
该研究在大鼠AdTGF-β1诱导的肺纤维化模型中,从第14天至第28天每日灌胃马西替坦(100 mg·kg-1·day-1)、吡非尼酮(0.5%饲料混饲)或两药联合。结果显示马西替坦降低肺动脉压升高,马西替坦和吡非尼酮均阻止纤维化进展;马西替坦还保护内皮细胞免于肌纤维母细胞分化和凋亡,而吡非尼酮仅抑制成纤维细胞向肌纤维母细胞分化。
要点
- 马西替坦可降低AdTGF-β1大鼠的肺动脉压升高并阻止肺纤维化进展。
- 吡非尼酮仅阻止肺纤维化进展,对肺动脉高压无影响。
- 马西替坦保护内皮细胞免于肌纤维母细胞分化和凋亡。
核心结论
- 双内皮素受体拮抗对肺动脉高压和肺纤维化均有效,而吡非尼酮仅影响纤维化。
研究设计与样本
- Sprague Dawley大鼠接受AdTGF-β1诱导肺纤维化,从第14天至第28天每日灌胃马西替坦(100 mg·kg-1·day-1)、吡非尼酮(0.5%饲料混饲)或联合治疗。
- 处死前测量肺动脉压,随后通过形态计量学和羟脯氨酸分析评估纤维化。
主要发现
- AdTGF-β1诱导的肺纤维化伴随显著肺动脉高压。
- 马西替坦降低肺动脉压升高,马西替坦和吡非尼酮均从第14天至第28天阻止纤维化进展。
- 马西替坦保护内皮细胞免于肌纤维母细胞分化和凋亡,吡非尼酮仅保护成纤维细胞向肌纤维母细胞分化。
- 两药在体外和体内均诱导分化肌纤维母细胞凋亡。
临床怎么用
- 马西替坦可能对IPF相关肺动脉高压及纤维化进展有双重获益,但需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with an unknown cause. Two drugs, nintedanib and pirfenidone, have been shown to slow, but not stop, disease progression. Pulmonary hypertension (PH) is a frequent complication in IPF patients and is associated with poor prognosis. Macitentan is a dual endothelin receptor antagonist that is approved for pulmonary arterial hypertension treatment. We hypothesised that using macitentan to treat animals with pulmonary fibrosis induced by adenoviral vector encoding biologically active transforming growth factor-β1 (AdTGF-β1) would improve the PH caused by chronic lung disease and would limit the progression of fibrosis.Rats (Sprague Dawley) which received AdTGF-β1 were treated by daily gavage of macitentan (100 mg·kg-1·day-1), pirfenidone (0.5% food admix) or a combination from day 14 to day 28. Pulmonary artery pressure (PAP) was measured before the rats were killed, and fibrosis was subsequently evaluated by morphometric measurements and hydroxyproline analysis.AdTGF-β1 induced pulmonary fibrosis associated with significant PH. Macitentan reduced the increase in PAP and both macitentan and pirfenidone stopped fibrosis progression from day 14 to day 28. Macitentan protected endothelial cells from myofibroblast differentiation and apoptosis whereas pirfenidone only protected against fibroblast-to-myofibroblast differentiation. Both drugs induced apoptosis of differentiated myofibroblasts in vitro and in vivoOur results demonstrate that dual endothelin receptor antagonism was effective in both PH and lung fibrosis whereas pirfenidone only affected fibrosis.
引用
- Bellaye PS, Yanagihara T, Granton E, et al. Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension. Eur Respir J. 2018. PMID: 29976656. doi:10.1183/13993003.01857-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。